TY - JOUR
T1 - Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel
AU - Aradi, Dániel
AU - Kuliczkowski, Wiktor
AU - Atar, Dan
AU - Serebruany, Victor L.
PY - 2012
Y1 - 2012
N2 - Although there is considerable variability of platelet reactivity among patients treated with clopidogrel, little is known about inter-individual differences and possible role of proton pump inhibitors (PPIs) after prasugrel. We defined the extent of inter-patient variability, and evaluated the impact of PPI interaction in prasugrel-treated patients with acute coronary syndrome (ACS). Between January 2010 and May 2011, 104 prospective, high-risk patients with ACS were recruited into this multicentre, prospective, observational study. Twelve to 24 hours after receiving 60 mg loading dose of prasugrel, light transmission aggregometry (LTA) and whole blood impedance aggregometry (Multiplate) were used to assess platelet activity. Platelet function measurements were repeated during maintenance phase on reduced (5 mg) or on conventional (10 mg) doses of prasugrel. High platelet reactivity (HPR) was defined according to the consensus document of the Working Group on High On-Treatment Platelet Reactivity (LTA:>46%; Multiplate:>47U). Compared to maintenance doses, 60 mg loading dose of prasugrel pro-vided significantly greater platelet reactivity inhibition (p
AB - Although there is considerable variability of platelet reactivity among patients treated with clopidogrel, little is known about inter-individual differences and possible role of proton pump inhibitors (PPIs) after prasugrel. We defined the extent of inter-patient variability, and evaluated the impact of PPI interaction in prasugrel-treated patients with acute coronary syndrome (ACS). Between January 2010 and May 2011, 104 prospective, high-risk patients with ACS were recruited into this multicentre, prospective, observational study. Twelve to 24 hours after receiving 60 mg loading dose of prasugrel, light transmission aggregometry (LTA) and whole blood impedance aggregometry (Multiplate) were used to assess platelet activity. Platelet function measurements were repeated during maintenance phase on reduced (5 mg) or on conventional (10 mg) doses of prasugrel. High platelet reactivity (HPR) was defined according to the consensus document of the Working Group on High On-Treatment Platelet Reactivity (LTA:>46%; Multiplate:>47U). Compared to maintenance doses, 60 mg loading dose of prasugrel pro-vided significantly greater platelet reactivity inhibition (p
KW - ADP receptors
KW - Antiplatelet agents
KW - Antiplatelet drugs
KW - Platelet pharmacology
UR - http://www.scopus.com/inward/record.url?scp=84856682448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856682448&partnerID=8YFLogxK
U2 - 10.1160/TH11-09-0622
DO - 10.1160/TH11-09-0622
M3 - Article
C2 - 22186910
AN - SCOPUS:84856682448
SN - 0340-6245
VL - 107
SP - 338
EP - 345
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 2
ER -